– USA, MA – Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced the appointment of Dr. Jessica Hopfield to its Board of Directors.
Dr. Hopfield is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice and is currently the Chair of the Board of Trustees of the Joslin Diabetes Center. She also serves on the Board of Directors of Insulet Corporation and Editas Medicine.
“We are very pleased to welcome Jessica to our Board,” said Kurt Graves, Chairman of the Board of Radius. “Jessica brings more than two decades of healthcare experience, significant Board experience, and a wealth of strategic advisory experience that she brought to a range of pharmaceutical and biotech companies. We welcome her contributions as Radius continues making progress advancing its late-stage clinical pipeline and becoming a leader in the treatment of osteoporosis and breast cancer.”
“Jessica brings to our Board a unique combination of expertise in the field of osteoporosis and extensive experience providing strategic advice to biopharma companies, including in the oncology space,” said Jesper Høiland, President and Chief Executive Officer of Radius. “We look forward to benefiting from her strategic guidance as we shape Radius for sustained long-term success.”
About Dr Jessica Hopfield
Dr. Hopfield has served on the Board of Trustees of the Joslin Diabetes Center since 2013, initially as the Vice Chair, and since 2015, as the Chair. She has served on the Board of Directors of Insulet since July 2015 and as its Lead Independent Director from August 2016 to December 2018. Since February 2018, Dr. Hopfield has served on the Board of Editas. She has been the President of J Hopfield Consulting providing strategic guidance to and investing in start-up technology firms since 2010. From 1995 to 2009, Dr. Hopfield was a Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice, where she served clients across pharmaceutical, biotechnology, medical device, and consumer industries. She also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing. Dr. Hopfield earned a B.S. from Yale College, an M.B.A. from Harvard Graduate School of Business Administration as a Baker Scholar, and a Ph.D. in Neuroscience/Biochemistry from The Rockefeller University.
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology.
For more information : https://www.radiuspharm.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.